Nine healthtech investors back Singapore startups in 2026. EDBI and A*STAR anchor government-backed rounds. B Capital writes the largest growth cheques. Singapore's regulatory sandbox and MOH pilot programs create a unique clinical validation advantage.
Singapore is Southeast Asia's primary hub for healthtech clinical validation. MOH Holdings and SingHealth run structured pilot programs for digital health companies.
A*STAR provides research co-funding that extends runway before VC capital enters. Healthtech founders who tap A*STAR grants reach clinical validation at 30% lower equity dilution.
Singapore's aging population creates structural demand for eldercare tech and chronic disease management. MOH's Healthier SG initiative is a direct market-entry channel for qualifying healthtech startups.
This guide covers 9 active healthtech investors in Singapore writing cheques in 2026.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| EDBI | Gov strategic VC | $5M-$50M | Healthtech, medtech, pharma, biotech | edbi.com |
| Vertex Ventures SEA | Seed to Series A | $1M-$15M | Healthtech, enterprise, B2B | vertexventures.com |
| B Capital Group | Growth VC | $20M-$100M | Health AI, digital health, med devices | bcapital.com |
| Openspace Ventures | Seed to Series B | $2M-$15M | Healthtech, digital health, SEA | openspace.vc |
| Novo Holdings | Life science VC | $10M-$100M | Pharma, biotech, digital health | novoholdings.dk |
| Jungle Ventures | Series A VC | $5M-$30M | Healthtech, consumer, enterprise | jungle.vc |
| A*STAR Ventures | Gov research VC | $500K-$10M | Deep biotech, medtech, AI health | astar.edu.sg |
| InnoVen Capital | Venture debt | $2M-$15M | Growth-stage healthtech and medtech | innovencapital.com |
| Helios Investment | Growth healthcare | $20M-$100M | Pan-Asian healthcare, hospitals, pharma | heliosinvestment.com |
Track your Singapore healthtech investor pipeline
Ellty shows who opened your pitch and when. Follow up while investors are reviewing your clinical data.
Start free 14-day trialWhat Singapore healthtech VCs look for
Singapore healthtech VCs require clinical evidence or a clear regulatory pathway from seed stage. Founders without a device or software classification from HSA face harder investor conversations.
SingHealth or NUH pilot data is worth more than market size slides at Singapore Series A. A real-world clinical pilot converts VC meeting interest into term sheets 3x faster.
Share your clinical pilot data and pitch materials through a data room with controlled access per investor. Healthtech due diligence involves clinicians, regulators, and investors - control who sees what.
Southeast Asia regional regulatory roadmap is expected before institutional Series A. Each ASEAN market has different health device regulations - show you've mapped them all.
Singapore healthtech founders who start with a SingHealth or NUH pilot and real clinical data cut 12 months off their Series A timeline. Clinical evidence is the only proof of concept that matters here.
9 Singapore healthtech investors
1. EDBI (EDB Investments)
Singapore government's corporate fund - best access point to MOH and HSA network.
Recent Deals: Singapore healthtech government investments 2025-2026; MOH innovation program connections active
LinkedIn: EDBI (EDB Investments) LinkedIn
Sector Focus: Healthtech, medtech, biotech
Stage Focus: Series A to growth
Location: Singapore
Website: edbi.com.sg
2. Vertex Ventures SEA
Singapore's most prolific healthtech fund with regional hospital network connections.
Recent Deals: SEA healthtech investments 2025; hospital network and clinical pilot connections active
LinkedIn: Vertex Ventures SEA LinkedIn
Sector Focus: Healthtech, medtech, diagnostics
Stage Focus: Seed to Series B
Location: Singapore
Website: vertexventures.com
3. B Capital Group
Crossover fund with BCG Health distribution and the deepest enterprise healthtech network.
Recent Deals: Enterprise healthtech investments 2025; BCG Health and hospital system distribution network
LinkedIn: B Capital Group LinkedIn
Sector Focus: Healthtech, enterprise, digital health
Stage Focus: Series A to growth
Location: Singapore
Website: bcapital.com
4. Openspace Ventures
Most active SEA healthtech fund with cross-border clinical trial and hospital network.
Recent Deals: SEA healthtech investments 2025; clinical trial and hospital network connections in 6 markets
LinkedIn: Openspace Ventures LinkedIn
Sector Focus: Healthtech, diagnostics, medtech
Stage Focus: Seed, Series A
Location: Singapore
Website: openspace.vc
5. Novo Holdings
Novo Nordisk's investment arm with active Singapore biotech and digital health mandate.
Recent Deals: Singapore digital health and biotech investments 2025-2026; Biopolis network active
LinkedIn: Novo Holdings LinkedIn
Sector Focus: Healthtech, biotech, pharma
Stage Focus: Series A to growth
Location: Singapore
Website: novoholdings.dk
6. Jungle Ventures
Singapore's leading B2B fund - backs healthtech SaaS with ASEAN hospital distribution.
Recent Deals: Healthtech SaaS investments 2025; ASEAN hospital distribution and clinical pilots active
LinkedIn: Jungle Ventures LinkedIn
Sector Focus: Healthtech SaaS, B2B, ASEAN
Stage Focus: Series A, B
Location: Singapore
Website: jungle.vc
Track who's reading your Singapore healthtech pitch
Ellty shows you which healthtech VCs opened your deck and what slides they focused on.
Start free 14-day trial7. A*STAR Ventures
Singapore's national research agency CVC with deep Biopolis network connections.
Recent Deals: A*STAR spin-out and healthtech investments 2025-2026; Biopolis commercialization active
LinkedIn: A*STAR Ventures LinkedIn
Sector Focus: Healthtech, biotech, medtech
Stage Focus: Seed, Series A
Location: Singapore
Website: a-star.edu.sg
8. InnoVen Capital
Singapore's leading venture debt for healthtech at Series A+ stage.
Recent Deals: Venture debt for Series A+ healthtech 2025-2026; Singapore, India and China portfolio active
LinkedIn: InnoVen Capital LinkedIn
Sector Focus: Healthtech, venture debt, growth
Stage Focus: Series A to growth
Location: Singapore
Website: innovencapital.com
9. Helios Investment Partners
Africa-focused fund with Singapore HQ and active digital health emerging market thesis.
Recent Deals: Digital health investments 2025; Singapore HQ for emerging market healthtech portfolio active
LinkedIn: Helios Investment Partners LinkedIn
Sector Focus: Digital health, emerging markets
Stage Focus: Series A to growth
Location: Singapore
Website: heliosinvestment.com
HSA regulation: Singapore's health advantage
Singapore's Health Sciences Authority is the fastest major health regulator in Asia. HSA device approvals take 6-12 months - faster than FDA (12-24 months) or PMDA (18-30 months).
HSA-cleared devices get immediate recognition in Australia, Canada, and EU markets. A Singapore HSA clearance is the lowest-cost path to multi-market medical device access.
Organize your regulatory filing documents in a cap table management and document system from day one. Healthtech deals involve IP, regulatory filings, and clinical data - all need controlled access.
MOH's Licensing and Certification Division provides pre-submission meetings for free. Book these before filing - HSA rejections cost 6 months and are entirely avoidable.
Singapore healthtech funding by stage
Pre-seed and seed healthtech rounds in Singapore run $500K-$3M with A*STAR or MOH pilot data. Antler and 500 Global write the fastest early cheques for founders at idea stage.
Series A rounds run $5M-$20M and require real patient data and hospital LOIs. Vertex and Openspace are the most active Singapore Series A investors in 2026.
Track your fundraising pipeline with investor relations tools designed for multi-stage investor management. Healthtech raises often involve parallel conversations with corporate, government, and VC investors.
Series B and growth rounds run $20M-$100M and require multi-market commercial traction. B Capital and Novo Holdings are the primary Singapore growth-stage healthtech investors.
Singapore healthtech due diligence
Singapore healthtech VCs run clinical evidence, regulatory, and IP ownership diligence. Have your HSA classification, clinical data, and IP assignment documents ready before Series A.
Cybersecurity and patient data protection are reviewed at every stage in Singapore. PDPA compliance and health data residency requirements must be documented and implemented.
Share your diligence package through a term sheet negotiation data room to manage multiple investor access levels. Healthtech diligence involves clinicians, lawyers, and financial reviewers with different access needs.
Independent clinical advisory boards signal credibility to Singapore institutional VCs. A 3-person clinical advisory board with SingHealth or NUH affiliations accelerates every VC conversation.
How to pitch a Singapore healthtech investor
Lead with clinical evidence and HSA regulatory status. Both are filters every VC applies first.
- 1.Get a MOH or SingHealth pilot letter firstA hospital LOI beats any market size slide. Apply 9 months before your raise.
- 2.Apply to A*STAR co-funding before seed raiseA*STAR co-investment extends your runway and validates your research approach.
- 3.Get HSA device classification earlyA Class A or B classification takes 3 months and opens all institutional doors.
- 4.Send deck with clinical data via ElltyKnow when investors open your clinical section. Follow up within 24 hours.
- 5.Follow up once after 10 business daysSingapore health VCs are methodical. One clear follow-up is all you need.
How Ellty helps you land a healthtech investor in Singapore
Ellty is a data room for healthtech founders. Track VC interest and follow up at the right time.
- 1.Organise your health fundraising documentsAdd deck, clinical data, and regulatory filings. Set access per investor.
- 2.Share trackable links with Singapore VCsSend each VC a unique link. Ellty logs every open and time per section.
- 3.Follow up when VCs are reviewing clinical dataSee which VCs opened your files today. Follow up within 24 hours.
Singapore healthtech investors: common questions
- Seed rounds run $500K-$3M. A*STAR and EDBI co-invest from pre-seed stage.
- Chronic disease, elder care, AI diagnostics, and digital therapeutics lead Singapore mandates.
- Seed closes in 6-10 weeks. Series A with EDBI or Vertex takes 12-18 weeks with clinical diligence.
- Not for seed. Series A investors typically require HSA classification or a clear filing timeline.
- 3-6 months of real patient data from a Singapore hospital pilot is the minimum for Series A.
